Lallemand closes licensing deal with Proge Farm for its women’s health probiotic
Lallemand Health Solutions and Proge Farm closed a licensing deal for the commercialization of Proge Farm’s probiotic strain L. plantarum P17630 (Proge P17630), which has specific women health benefits.
Photo © iStockphoto.com/rzdeb
Lallemand Health Solutions (Mirabel, Canada) and Proge Farm (Novara NO, Italy) closed a licensing deal for the commercialization of Proge Farm’s probiotic strain L. plantarum P17630 (Proge P17630), which has specific women health benefits.
“Proge Farm’s highly documented probiotic strain L. plantarum P17630 is a valuable new asset in Lallemand Health Solution’s Women’s health probiotic range,” said Isabelle Champié, vice president sales and marketing at Lallemand Health Solutions, in a press release. “Women’s health is gaining more importance in the probiotics market, as consumers are increasingly looking for natural ways to take care of their intimate health. Furthermore, with this specific strain, it will be even easier to do so with one daily dose taken orally.”
Giancarla Dondi, owner and CEO of Proge Farm said Lallemand Health Solutions will be able to widely disseminate its probiotic strain, “meaning more women will benefit from its compelling effects,” she said in a press release.
The licensing commercialization agreement includes the following territories: Asia, Americas, France, and Czech Republic. Lallemand Health Solutions will launch this new offer in September at the Vitafoods Virtual Expo (Sept. 7-11, 2020).
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
